Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer

Inclusion Criteria: PLANNED PROSTATECTOMY * Biopsy-proven prostate adenocarcinoma * Intermediate to high-risk disease, defined as one of the following factors: PSA \> 10, T2b or greater, or a Gleason score of 7 or greater. * Planned prostatectomy with lymph node dissection * Must be treatment naïve (not have received neoadjuvant chemotherapy, radiation therapy, hormonal therapy, androgen deprivation therapy, or focal ablation techniques (e.g., HiFu) BIOCHEMICAL RECURRENCE * Pathologically proven prostate adenocarcinoma. Rising PSA after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy). * If post-radical prostatectomy, PSA \> 0.2 ng/mL measured \> 6 weeks post-operatively and confirmatory persistent PSA greater than 0.2 ng/mL (AUA recommendation for biochemical recurrence). * If post-radiation therapy, PSA that is equal to or greater than a 2 mg/mL rise above PSA nadir (ASTRO recommendation for biochemical recurrence). * No other malignancy within the past 2 years (skin basal cell or cutaneous superficial squamous cell carcinoma or superficial bladder cancer are exempt from this criterion). ALL * Karnofsky performance status (KPS) \>= 50 (ECOG/WHO 0, 1, or 2) * Not receiving any other investigational agents (i.e., unlabeled drugs or drugs under an IND for initial efficacy investigations * Ability to understand and the willingness to provide informed consent Exclusion Criteria: * History of Stevens-Johnson syndrome * Known Paget's disease * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.